Endoscope Reprocessing Market Overview, Leading Players and Forecast Report 2030

In 2021, the endoscope reprocessing market was worth around USD 1,879.9 million, and it is projected to advance at a 9.8% CAGR from 2021 to 2030, hitting USD 4,358.1 million by 2030, according to P&S Intelligence. 

This growth can be credited to the increasing leaning toward minimally invasive methods, the spreading risk of numerous contaminations related with contaminated endoscopes, and the rising strict government guidelines spanning throughout the world to control such infections.

In 2021, the high-level disinfectants and test strips category, held the market share of around 35%, credited to the increasing occurrence of numerous endogenous infections, including bacteremia and pneumonia, after the usage of endoscopy measures. 

Likewise, the acceptance of test strips is also growing for the operative measurement of minimum effective concentration (MEC) required for high-level decontamination, thus offering quicker disinfection response time. Furthermore, it supports in the finding of hemoglobin, residual proteins and carbohydrates on both flexible and stiff endoscopes, via color comparison chart.

In 2021, the Endoscope reprocessing is predominantly used in flexible endoscopes, dominated the market with largest market share of approximately 65.0%. This is mainly due to key players in the industry are vigorously introducing AERs that are decidedly well-suited with flexible endoscopes.

For example, around 90% of businesses are emerging AERs for flexible endoscopes, because of their probability to control and lighter weight. In October 2021, FUJIFILM Corporation declared the launch of the El-740D/S flexible endoscope, which is the only dual-channel flexible endoscope permitted by the FDA for upper and also lower gastrointestinal utilization.

In the coming few years, the hospitals category is projected to witness highest CAGR, of approximately 11% in the market. This can be credited to the increasing count of endoscopy procedures attached with the growing count of hospitals throughout the globe, and the declaration of capitals and investments offered by government bodies.

North America held the largest revenue share of approximately 1.0 billion, in the endoscope reprocessing market. This can be ascribed to the increase in fondness for minimally invasive methods, outgrowth in cancer cases, and supportive repayment situations in the continent. For example, the Indian government amplified its healthcare spending to approximately 1.8% of its GDP in 2021– 2022, which was approximately 1.5% in 2020–2022.

Furthermore, the existence of massive manufacturers of medicinal devices, including Stryker Corporation, Boston Scientific Corporation, Cantel Medical Corp., and Conmed Corporation leads to the simple obtainability of not only endoscopes but also OEM repair facilities.

Hence, increasing leaning toward minimally invasive methods, the spreading risk of numerous contaminations related with contaminated endoscopes, and the rising strict government guidelines spanning throughout the world to control such infections, are the major factors propelling endoscope reprocessing market. 

Report this Page